Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.43 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL8676368 | 1.00 | LMNA (0.50) | LMNAGPR84CA1FFAR1MAPT | |
| Hexane SCHEMBL4557975 | 1.00 | LMNA (0.50) | LMNAGPR84CA1FFAR1MAPT | |
| Hexane SCHEMBL2810416 | 1.00 | LMNA (0.50) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL9365266 | 1.00 | LMNA (0.50) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL15347870 | 0.98 | LMNA (0.54) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL6274726 | 0.95 | LMNA (0.50) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL17676315 | 0.93 | LMNA (0.54) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL5014419 | 0.93 | LMNA (0.54) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL13938058 | 0.93 | LMNA (0.54) | LMNAGPR84CA1FFAR1MAPT | |
| SCHEMBL17676311 | 0.93 | LMNA (0.54) | LMNAGPR84CA1FFAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390437-B2 | Pharmaceutical formulation | GW Research Limited (GB) | 2022-07-19 | — | — | US | disclosed |
| US-20210221587-A1 | PHARMACEUTICAL FORMULATION | GW PHARMA LIMITED (GB) | 2021-07-22 | — | — | US | disclosed |
| US-10807777-B2 | Pharmaceutical formulation | GW PHARMA LIMITED (GB) | 2020-10-20 | — | — | US | disclosed |
| US-20200102131-A1 | PHARMACEUTICAL FORMULATION | GW PHARMA LIMITED (GB) | 2020-04-02 | — | — | US | disclosed |
| US-20190322427-A1 | PHARMACEUTICAL FORMULATION | GW PHARMA LIMITED (GB) | 2019-10-24 | — | — | US | disclosed |
| US-20190270563-A1 | PHARMACEUTICAL FORMULATION | GW PHARMA LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-10179683-B2 | Pharmaceutical formulation | GW PHARMA LIMITED (GB) | 2019-01-15 | — | — | US | disclosed |
| EP-3074382-B1 | PELORUSIDE ANALOGS | UNIV GENT (BE) | 2017-11-15 | — | — | EP | disclosed |
| US-9771344-B2 | Peloruside analogs | UNIVERSITEIT GENT (BE) | 2017-09-26 | — | — | US | disclosed |
| EP-2314284-B1 | Cannabinoid liquid formulations for mucosal administration | GW PHARMA LTD (GB) | 2017-02-15 | — | — | EP | disclosed |
| US-6946150-B2 | Lipophilic medicament, a solvent and a co-solvent in an amount > 55% wt/wt of the formulation; free from self emulsifying agent and/or a fluorinated propellant; cannabinoids administered by a pump action spray | GW PHARMA LIMITED (GB) | 2005-09-20 | — | — | US | disclosed |
| EP-1542657-A1 | CANNABINOID LIQUID FORMULATIONS FOR MUCOSAL AMDINISTRATION | GW Pharma Limited (GB) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004016246-A1 | CANNABINOID LIQUID FORMULATIONS FOR MUCOSAL AMDINISTRATION | GW PHARMA LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| US-20040034108-A1 | Lipophilic medicament, a solvent and a co-solvent in an amount > 55% wt/wt of the formulation; free from self emulsifying agent and/or a fluorinated propellant; cannabinoids administered by a pump action spray | U.S. BANK NATIONAL ASSOCIATION | 2004-02-19 | — | — | US | disclosed |
| EP-1087961-B1 | PHENOXYLPROPANOLAMINES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SANOFI SYNTHELABO (FR) | 2002-08-14 | — | — | EP | disclosed |
| EP-1087961-A1 | PHENOXYLPROPANOLAMINES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SANOFI-SYNTHELABO (FR) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065895-A1 | PHENOXYLPROPANOLAMINES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SANOFI-SYNTHELABO (FR) | 1999-12-23 | — | — | WO | disclosed |
| EP-0070588-B1 | METHOD OF PREPARING 1-ALPHA-HYDROXYVITAMIN D AND 1-ALPHA-HYDROXY-PREVITAMIN D COMPOUNDS, AND ADDUCT OF A PREVITAMIN D OR TACHYSTEROL COMPOUND WITH A SUITABLE DIENOPHILE | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1986-05-07 | — | — | EP | disclosed |
| US-4539153-A | Method of preparing 1 α-hydroxyvitamin D and 1 α-hydroxyprevitamin D compounds, and adducts of a previtamin D or tachysterol compound with a suitable dienophile | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1985-09-03 | — | — | US | disclosed |
| EP-0070588-A1 | Method of preparing 1-alpha-hydroxyvitamin D and 1-alpha-hydroxy-previtamin D compounds, and adduct of a previtamin D or tachysterol compound with a suitable dienophile | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1983-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034108-A1 | Lipophilic medicament, a solvent and a co-solvent in an amount > 55% wt/wt of the formulation; free from self emulsifying agent and/or a fluorinated propellant; cannabinoids administered by a pump action spray | CNR1, CNR2, FAAH | LMNA 1712/4885GPR84 208/4885CA1 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.